- Home
- AQB vs AZTR Comparison
AQB vs AZTR Comparison
Compare AQB & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- AZTR
- Stock Information
- Founded
- AQB 1991
- AZTR 2014
- Country
- AQB United States
- AZTR United States
- Employees
- AQB N/A
- AZTR N/A
- Industry
- AQB
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- AZTR Health Care
- Exchange
- AQB Nasdaq
- AZTR Nasdaq
- Market Cap
- AQB 3.4M
- AZTR 3.6M
- IPO Year
- AQB N/A
- AZTR 2023
- Fundamental
- Price
- AQB $0.58
- AZTR $0.42
- Analyst Decision
- AQB Hold
- AZTR
- Analyst Count
- AQB 2
- AZTR 0
- Target Price
- AQB N/A
- AZTR N/A
- AVG Volume (30 Days)
- AQB 838.2K
- AZTR 149.9K
- Earning Date
- AQB 11-05-2024
- AZTR 11-12-2024
- Dividend Yield
- AQB N/A
- AZTR N/A
- EPS Growth
- AQB N/A
- AZTR N/A
- EPS
- AQB N/A
- AZTR N/A
- Revenue
- AQB $1,258,512.00
- AZTR $97,500.00
- Revenue This Year
- AQB N/A
- AZTR $494.75
- Revenue Next Year
- AQB $57.38
- AZTR N/A
- P/E Ratio
- AQB N/A
- AZTR N/A
- Revenue Growth
- AQB N/A
- AZTR N/A
- 52 Week Low
- AQB $0.47
- AZTR $0.38
- 52 Week High
- AQB $3.00
- AZTR $68.40
- Technical
- Relative Strength Index (RSI)
- AQB 30.45
- AZTR 38.62
- Support Level
- AQB $0.47
- AZTR $0.38
- Resistance Level
- AQB $1.00
- AZTR $0.51
- Average True Range (ATR)
- AQB 0.14
- AZTR 0.03
- MACD
- AQB -0.02
- AZTR -0.01
- Stochastic Oscillator
- AQB 21.18
- AZTR 31.84
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.